10:00 - 20.06.2026

---

June 20, Fineko/abc.az. The Office of the United States Trade Representative (USTR) has officially initiated an investigation under Section 301 of the Trade Act of 1974 to determine whether Germany’s low reimbursement practices for innovative pharmaceuticals suppress US commerce and innovation.

According to ABC.AZ, the USTR confirmed that the formal probe was triggered following months of stagnant consultations with German health authorities regarding what Washington classifies as "unjust and discriminatory pricing mechanisms."

Core Parameters of the Trade Conflict:

• The Core Grievance: US trade officials argue that Germany's current regulatory framework effectively shifts the disproportionate financial burden of global pharmaceutical Research and Development (R&D) directly onto the US market. Key practices under review include Germany demanding deep statutory discounts in exchange for price confidentiality, alongside enforcing mandatory variable rebate structures.

• Procedural Timelines: The USTR has directed all impacted industry stakeholders to submit written briefs by August 10. Concurrently, a public evidentiary hearing has been scheduled for September 22.

• Official Pushback: US Trade Representative Jamieson Greer expressed deep concern over reports indicating that Berlin is fast-tracking a new legislative package aimed at further depressing cutting-edge drug expenditures. Greer framed the maneuver as a "serious step backward" at a time when global trading partners should be equitably funding medical breakthroughs, calling on Germany to engage in constructive, high-level structural negotiations to rebalance the trade corridor.